Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (germany) - antithrombin iii - powder and solvent for solution for infusion - 500unit

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (germany) - antithrombin iii - powder and solvent for solution for infusion - 1000unit

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ix 1000 [iu] (100iu/ml when reconstituted with 10ml water for injection) - injection with diluent - 1000 iu - active: factor ix 1000 [iu] (100iu/ml when reconstituted with 10ml water for injection) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) - injection with diluent - 500 iu - active: factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) - injection with diluent - 50 iu/ml - active: factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Izrael - angielski - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in minor surgery, and as a prophylaxis in patients with haemophilia b. it has not been evaluated in major surgery. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels fo these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors. indications as at 14 may 1999: monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because is does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Singapur - angielski - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - immunology - n as atiii is an in vitro diagnostic reagent for the quantitative determination of antithrombin concentration as aid to diagnosis and monitoring of congenital or acquired antithrombin deficiencies in patients at risk for or suspected to have antithrombin deficiency in human sodium citrated plasma by means of immunonephelometry using the automated siemens healthineers immuno-nephelometry systems. n as atiii uses a calibration against an internal protein reference preparation.

Wielka Brytania - angielski - HMA (Heads of Medicines Agencies)

animedica gmbh - heparin sodium 50 iu, hydroxyethyl salicylate 50 mg/g, levomenthol 5 mg/g - gel - horses food - preparations with salicylic acid derivatives, combinations

Austria - angielski - HMA (Heads of Medicines Agencies)

animedica gmbh - heparin sodium 50 iu, hydroxyethyl salicylate 50 mg/g, levomenthol 5 mg/g - gel - horses food - preparations with salicylic acid derivatives, combinations